Clinical Trial

BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)

Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care

Jaguar planning to begin commercial launch of FDA-approved Gelclair® prescription gel for oral mucositis (also called “chemo mouth”) in Q3...

Lindis Blood Care Announces Positive Top-Line Results from Clinical Certification Study REMOVE with CATUVAB(R) to Enable Autologous Blood Transfusions in Cancer Surgeries

CATUVAB® procedure enables highly effective removal of malignant cells from intraoperative blood. All clinical endpoints met with high statistical significance.Convincing...

VIVUS Announces it will Provide Telehealth to Patients through an Enhanced ‘Engage’ Program in Collaboration with UpScriptHealth

Collaboration will deliver a seamless telehealth experience, providing patients with immediate access to QSYMIA®, a chronic weight loss medication, enhancing...

ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of...

Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California

Cannabix is developing Marijuana Breathalyzer devices to give law enforcement and employers a tool to enhance public safetyVANCOUVER, British Columbia,...

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

Boca Raton, Florida, April 22, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused...

Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis

Nes-Ziona, Israel, April 22, 2024 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...

error: Content is protected !!